{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "37880142",
  "DateCompleted": {
    "Year": "2023",
    "Month": "12",
    "Day": "29"
  },
  "DateRevised": {
    "Year": "2024",
    "Month": "01",
    "Day": "02"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2023",
        "Month": "10",
        "Day": "25"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1021/acs.jmedchem.3c01607"
    ],
    "Journal": {
      "ISSN": "1520-4804",
      "JournalIssue": {
        "Volume": "66",
        "Issue": "24",
        "PubDate": {
          "Year": "2023",
          "Month": "Dec",
          "Day": "28"
        }
      },
      "Title": "Journal of medicinal chemistry",
      "ISOAbbreviation": "J Med Chem"
    },
    "ArticleTitle": "Clinical Translation of Aptamers for COVID-19.",
    "Pagination": {
      "StartPage": "16568",
      "EndPage": "16578",
      "MedlinePgn": "16568-16578"
    },
    "Abstract": {
      "AbstractText": [
        "The COVID-19 etiologic agent, SARS-CoV-2, continues to be one of the leading causes of death on a global scale. Although efficient methods for diagnosis and treatment of COVID-19 have been developed, new methods of battling SARS-CoV-2 variants and long COVID are still urgently needed. A number of aptamers have demonstrated tremendous potential to be developed into diagnostic and therapeutic agents for COVID-19. The translation of the aptamers for clinical uses, however, has been extremely slow. Overcoming the difficulties faced by aptamers would advance this technology toward clinical use for COVID-19 and other serious disorders."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-3503-5161"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "College of Science, Harbin Institute of Technology (Shenzhen), Shenzhen, Guangdong 518055, China."
          }
        ],
        "LastName": "Zhang",
        "ForeName": "Yang",
        "Initials": "Y"
      },
      {
        "Identifier": [
          "0009-0009-1803-6259"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "College of Science, Harbin Institute of Technology (Shenzhen), Shenzhen, Guangdong 518055, China."
          }
        ],
        "LastName": "Li",
        "ForeName": "Yongen",
        "Initials": "Y"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Med Chem",
    "NlmUniqueID": "9716531",
    "ISSNLinking": "0022-2623"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Oligonucleotides"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Post-Acute COVID-19 Syndrome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Oligonucleotides"
    }
  ]
}